Mineralys Therapeutics MLYS Ratios (2022-2026)

NASDAQ MLYS
$15.52 -0.29 (-1.83%)
At close: Nov 10, 2026 · 4:00 PM EST
Reported Financials

Mineralys Therapeutics Quarterly Ratios

Periods 18 quarters
Latest Sep 2026

Mineralys Therapeutics ratios data for the quarter ended Sep 2026. These financial ratios cover 18 quarters of results from Jun 2022 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

RatiosRatios Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Profitability
EBT Margin -1,001.75%-1,070.37%-641.39%-437.93%-747.88%-834.42%-917.78%-1,087.86%-1,592.63%-1,842.90%-1,985.13%-1,345.60%-980.48%-633.25%-756.17%-4,964.49%
EBIT Margin -1,001.75%-1,070.37%-641.39%-437.93%-747.88%-834.42%-917.78%-1,087.86%-1,592.63%-1,842.90%-1,985.13%-1,345.60%-980.48%-633.25%-756.17%-4,964.49%
EBITDA Margin -641.39%-437.93%-747.88%-834.42%-917.57%-1,087.64%-1,592.34%-1,842.36%-1,984.46%-1,345.14%-980.12%-633.04%-756.07%-4,964.39%
Operating Margin -1,001.75%-1,070.37%-641.39%-437.93%-747.88%-834.42%-917.78%-1,087.86%-1,592.63%-1,842.90%-1,985.13%-1,345.60%-980.48%-633.25%-756.17%-4,964.49%
Net Margin -901.21%-970.37%-541.35%-337.91%-647.88%-734.39%-817.75%-987.81%-1,492.90%-1,742.47%-1,885.26%-1,245.65%-880.38%-534.04%-656.09%-4,864.23%
FCF Margin -943.05%-1,089.41%-548.52%-567.38%-541.73%-872.66%-498.26%-726.06%-1,330.76%-2,379.60%-2,031.58%-868.42%-688.25%-627.01%-658.77%-656.32%
Efficiency
Assets AverageAssets Avg. 210.44M298.83M284.39M264.60M299.44M332.87M293.37M237.08M280.42M345.33M467.84M630.88M657.33M660.36M648.99M
Equity AverageEquity Avg. -33.70M-40.17M-47.84M121.80M290.44M274.51M252.58M284.60M309.07M263.51M214.09M266.41M327.55M444.99M611.56M642.42M594.53M527.35M
Invested CapitalInvested Cap. 646.69M648.53M602.05M
Asset Utilization RatioAsset Util. 0.020.030.040.050.050.040.050.060.050.040.030.030.030.03
Leverage & Solvency
Interest Coverage RatioInterest Cover -18.85
Debt Ratio 0.16
Times Interest Earned -18.85
Valuation
Price to SalesP/S 96.8391.6837.7027.7344.8739.1939.9042.0465.0772.32235.47153.91113.33112.48
Price to BookP/B 4.42
Enterprise Value 1,600.09M
Market Capitalization 2,224.77M
Return Ratios
Return on Sales [ROS]ROS -1,001.75%-1,070.37%-641.39%-437.93%-747.88%-834.42%-917.78%-1,087.86%-1,592.63%-1,842.90%-1,985.13%-1,345.60%-980.48%-633.25%-756.17%-4,964.49%
Return on Capital Employed [ROCE]ROCE -65.40%
Return on Assets [ROA]ROA -59.63%
Return on Equity [ROE]ROE -73.38%

Mineralys Therapeutics Ratios API

Pull Mineralys Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=MLYS&statement=Ratios&frequency=Quarter&period=all&api_key=YOUR_API_KEY